CEO Monthly May 2017

CEO MONTHLY / MAY 2017 29 , incredible diversity of specialist strains that typically prey upon just one strain of bacteria, enabling phage therapies to precisely target pathogenic bacteria while sparing the beneficial microbiota. Phages can infect and kill bacteria, whether they are antibiotic- resistant or not, and even when they have formed protective biofilms. About AmpliPhi Biosciences AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced an additional near-term strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults. AmpliPhi recently announced the completion of an underwritten public offering of common stock and common warrants resulting in net proceeds to AmpliPhi of approximately $9.1 million. More information is available at www.ampliphibio.com . and commercializing therapies that make a difference drew me to AmpliPhi Biosciences as a director, and I am thrilled to be assuming executive leadership of this exciting company. Our phage technology is much- needed in today’s world of antibiotic resistance which, if left unchecked, is projected to result in significant loss of life. AmpliPhi has the opportunity to be a meaningful player in addressing this looming public health crisis.” About Antibiotic Resistance Decades of misuse and over- use of antibiotics has led to the rise of multidrug-resistant and pan-resistant bacteria, commonly known as “superbugs.” These superbugs threaten to render existing antibiotic therapies useless, potentially thrusting the world into a “post-antibiotic” era where common infections may be life threatening. Hospitals regularly expose vulnerable patients to pathogenic bacteria. According to the World Health Organization, each year hundreds of millions of patients worldwide suffer from infections acquired in a hospital setting. The Centers for Disease Control and Prevention estimates that drug-resistant bacteria cause at least 2 million infections per year in the U.S. alone, resulting in over 23,000 deaths and many more people die from other conditions that are complicated by antibiotic-resistant infections. The 2016 O’Neill Report commissioned by the UK government projects that the failure to respond to the threat of antibiotic resistance and the rise of superbugs could lead to an estimated 10 million deaths per year from antibiotic-resistant infections worldwide by 2050, with an accumulated global cost of $100 trillion and a 3.5% reduction in global GDP. About Bacteriophages Bacteriophages, or more simply ‘phages,’ are the natural predators of bacteria and are thought to be the most abundant life form on earth. Over eons, phages have evolved an